

Environmental and Social Data Sheet

Overview

Project Name:	INNOVATIVE CELL THERAPIES (EGFF)
Project Number:	2019-0880
Country:	Germany
Project Description:	The promoter is a clinical-stage biotherapy company that use placental cells and its unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for conditions such as inflammation, ischemia, muscle injuries, haematological disorders and mucosal repair following a severe infection, as well as complications from COVID-19 infection.
EIA required:	no
Project included in Carbon Footprint Exercise ¹ :	no

(details for projects included are provided in section: “EIB Carbon Footprint Exercise”)

Environmental and Social Assessment

Environmental Assessment

The project does not require a full Environmental Impact Assessment (EIA) report: i) the research activities are not listed in any of the annexes of the related EU EIA Directive (2014/52/EU amending 2011/92/EU), and ii) the project will be carried out in existing facilities already authorised for similar activities and volumes.

The promoter’s R&D facilities and practices are in compliance with relevant national and EU regulations and the promoter maintains adequate internal procedures and management practices. The use of animal testing is minimised and in line with the EU Directive 2010/63/EU. In addition, the Company has adequate policies and procedures in place to outsource and manage clinical trials in the different regions of the world in accordance with the EU 536/2014 regulation. The clinical trials which are sponsored by the project are performed under regulated and strictly controlled conditions, in existing specialised facilities which are regularly inspected by competent authorities - EMA in Europe and/or national equivalent bodies in the rest of the world (e.g. FDA).

¹ Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO₂e/year absolute (gross) or 20,000 tonnes CO₂e/year relative (net) – both increases and savings.

Luxembourg, 23.04.2020

Other Environmental and Social Aspects

If successful, the project is expected to lead to important social benefits stemming from its focus on the development of novel treatments for diseases associated with substantial social and economic impact, (e.g. critical limb ischemia, acute radiation syndrome, intermittent claudication muscle regeneration following hip fracture, complications from coronavirus infection etc.) in Europe and worldwide. By co-investing in this project, the Bank will contribute to making novel and better treatments available for such diseases.

Conclusions and Recommendations

If successful, the project presents potentially high health and societal benefits for the wider society. Considering the above, and the promoter being fully compliant with the applicable EU directives, regulations and standards across all business lines and processes, the project is deemed acceptable for the Bank's financing under environmental and social terms.

PJ/SQM/ECSO 01.02.2019